NEUVOGEN
NEUVOGEN is a San Diego-based, pre-revenue clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines built on a proprietary activation technology, with a pipeline of 10 candidates led by NGEN-143 for non-small cell lung cancer.
- Company typePrivate
- Founded-
- HeadquartersSan Diego, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
What NEUVOGEN does
NEUVOGEN is a San Diego-based, privately held, clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines for solid tumors. The company applies a systems biology and data-driven engineering approach to build each vaccine from six genetically modified allogeneic tumor cell lines, enhanced with a proprietary activation technology designed to overcome peripheral tolerance and broaden tumor antigen presentation. Its lead candidate, NGEN-143, targets non-small cell lung cancer (NSCLC) and is supported by preclinical in vitro and in vivo data, including AACR 2025 data showing polyfunctional CD8+ T cell activation and improved survival when combined with anti-PD1 in mouse tumor models. The company has expanded a pipeline of 10 candidates (NGEN-143, -241, -121, -221, -181, -281, -261, -122, -242, -123) spanning NSCLC, prostate, colorectal, breast, head & neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.
The company is pre-revenue and not yet in clinical trials. Its business model contemplates future revenue from product sales following regulatory approval, supplemented by potential licensing, co-development, or acquisition transactions with larger pharmaceutical partners. Commercial distribution is expected to flow through hospital and specialty pharmacies and oncology centers, with the company signaling openness to partnership-based global commercialization. Scientific credibility has been reinforced by SAB additions including 2018 Nobel laureate James P. Allison and Padmanee Sharma of MD Anderson, and board leadership by former Amgen CEO Gordon Binder. A 2022 licensing agreement with ImaginAb provides CD8 Immuno-PET imaging for clinical trial pharmacodynamic readouts. No commercial customers, funding rounds, or revenue figures are disclosed in the available source data.
NEUVOGEN firmographics
Firmographics- Name
- NEUVOGEN
- Legal name
- NEUVOGEN, Inc.
- Website
- https://neuvogen.com
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 101–250 employees
- Short description
- NEUVOGEN is a San Diego-based, pre-revenue clinical-stage biotechnology company developing off-the-shelf, whole-cell therapeutic cancer vaccines built on a proprietary activation technology, with a pipeline of 10 candidates led by NGEN-143 for non-small cell lung cancer.
- Ownership category
- akta.pro rank
NEUVOGEN industry classification
Industry- Product category
- Therapeutic Cancer Vaccines
- NAICS
- Biological Product (except Diagnostic) Manufacturing (325414), Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254)
- SIC
- Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Therapeutic Vaccines (e.g., Cancer/Chronic Infection) (HLAIAEAG)
- akta.pro secondary industries
- Therapeutic Vaccines (cancer, chronic infection immunotherapy) (HLAAAEAB), Vaccine Technology Platforms (mRNA, viral vector, protein subunit, inactivated/live-attenuated, VLP, DNA) (HLAAAEAD)
Keywords
Where NEUVOGEN is headquartered
LocationHeadquarters
- HQ city
- San Diego
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
NEUVOGEN business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Others
Revenue model
- Therapeutic Cancer Vaccines: NEUVOGEN is a pre-revenue clinical-stage biotechnology company developing therapeutic whole cell cancer vaccines. The company has not yet commercialized any products. Revenue generation is expected through product sales following regulatory approval, with potential for licensing agreements, co-development partnerships, or outright acquisition by larger pharmaceutical companies.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
NEUVOGEN product offering
Product offeringCore offering
NEUVOGEN develops therapeutic whole cell cancer vaccines for solid tumor indications using a proprietary platform that combines six genetically modified allogeneic tumor cell lines per vaccine product. Each cell line is enhanced with proprietary activation technology to broaden tumor antigen presentation and drive broad T cell responses. Vaccines are manufactured as off-the-shelf, intradermally administered products, with the lead candidate NGEN-143 targeting non-small cell lung cancer and nine additional candidates covering prostate, colorectal, breast, head and neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.
Product overview
NEUVOGEN is a biotechnology company developing a platform of therapeutic whole cell cancer vaccines for solid tumors. The company's portfolio consists of ten product candidates (NGEN-143, NGEN-241, NGEN-121, NGEN-221, NGEN-181, NGEN-281, NGEN-261, NGEN-122, NGEN-242, and NGEN-123) targeting non-small cell lung cancer, prostate cancer, colorectal cancer, breast cancer, head and neck cancer, glioblastoma, bladder cancer, gastric cancer, ovarian cancer, and pancreatic cancer respectively. NGEN-143 for NSCLC is the lead program. Each vaccine is built on NEUVOGEN's proprietary whole tumor cell vaccine platform, which combines advanced bioinformatics for cell line selection, proprietary genetic engineering for enhanced tumor antigen expression, and a scalable manufacturing process. All products are designed as off-the-shelf, intradermally administered vaccines.
Differentiator
Problem solved
Functional benefit
Brands
- NGEN-143: Lead product candidate - off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC), comprising six genetically modified allogeneic tumor cell lines enhanced with proprietary activation technology
- NGEN-241
- NGEN-121
- NGEN-221
- NGEN-181
- NGEN-281
- NGEN-261
- NGEN-122
- NGEN-242
- NGEN-123
Products and services
- NGEN-143 NGEN-143 is NEUVOGEN's lead product candidate: an off-the-shelf therapeutic vaccine for non-small cell lung cancer (NSCLC) comprising six genetically modified allogeneic tumor cell lines, each enhanced with proprietary activation technology to broaden tumor antigen presentation and improve immune engagement. It is intended for oncology use and is administered intradermally in any clinical setting without patient-specific customization.
- NGEN-241 NGEN-241 is a therapeutic cancer vaccine product candidate for prostate cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-121 NGEN-121 is a therapeutic cancer vaccine product candidate for colorectal cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-221 NGEN-221 is a therapeutic cancer vaccine product candidate for breast cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-181 NGEN-181 is a therapeutic cancer vaccine product candidate for head and neck cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-281 NGEN-281 is a therapeutic cancer vaccine product candidate for glioblastoma (GBM), built on NEUVOGEN's proprietary activation technology platform.
- NGEN-261 NGEN-261 is a therapeutic cancer vaccine product candidate for bladder cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-122 NGEN-122 is a therapeutic cancer vaccine product candidate for gastric cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-242 NGEN-242 is a therapeutic cancer vaccine product candidate for ovarian cancer, built on NEUVOGEN's proprietary activation technology platform.
- NGEN-123 NGEN-123 is a therapeutic cancer vaccine product candidate for pancreatic cancer, built on NEUVOGEN's proprietary activation technology platform.
Quantifiable outcome
- NGEN-143 activates polyfunctional, cytotoxic T cells that efficiently kill human tumor cells in a caspase-3 dependent manner
- +2 more outcomes
Companies that use NEUVOGEN
Customer profileSegments2 records
Ideal customer profiles2 records
NEUVOGEN technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Integration1 record
Feature4 records
NEUVOGEN partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ImaginAbcoreNEUVOGEN and ImaginAb signed a multi-year non-exclusive licensing agreement for ImaginAb's 89Zr CD8 Immuno-PET imaging technology. Under the agreement, ImaginAb provides clinical doses of CD8 Immuno-PET imaging agents for integration into NEUVOGEN's therapeutic vaccine clinical trials, along with technical and clinical support. ImaginAb's PET imaging technology enables tracking and quantitative imaging of CD8 T cells in cancer patients, allowing NEUVOGEN to visualize tumor infiltrating lymphocytes and monitor CD8 T cell dynamics in response to their cancer vaccine therapies without requiring multiple tumor biopsies. ImaginAb receives license fees and contingent payments.
Scale indicators2 records
Recent moves6 records
Expansion highlights5 records
NEUVOGEN competitors and assessment
Company assessmentDirect peers
- Moderna: Moderna is developing mRNA-based personalized neoantigen cancer vaccines (mRNA-4157/V940) in partnership with Merck, targeting solid tumors including NSCLC. It competes with NEUVOGEN for the same therapeutic cancer vaccine opportunity but uses a personalized, patient-specific mRNA approach rather than an off-the-shelf whole-cell platform.
- BioNTech: BioNTech is developing mRNA-based cancer vaccines including BNT122 (autogene cevumeran) with Genentech/Roche, FixVac, and individualized neoantigen programs targeting solid tumors. It is the most advanced personalized cancer vaccine competitor to NEUVOGEN's whole-cell approach.
- Gritstone bio: Gritstone bio develops neoantigen-based immunotherapies (GRANITE and SLATE programs) targeting solid tumors using viral vectors and self-amplifying mRNA. It is a direct competitor in the personalized/neoantigen cancer vaccine space serving similar oncology indications as NEUVOGEN.
- CureVac: CureVac is developing mRNA-based cancer vaccines (CV8102 and others) for solid tumors and is partnering with major pharma. It competes with NEUVOGEN for the therapeutic cancer vaccine opportunity using an off-the-shelf mRNA technology approach.
Emerging players
- Nouscom: Nouscom is a clinical-stage biotech developing off-the-shelf and personalized neoantigen cancer vaccines using viral vectors. It is an emerging European player with overlapping therapeutic vaccine technology and solid tumor focus, comparable to NEUVOGEN's earlier-stage position.
- OSE Immunotherapeutics: OSE Immunotherapeutics is developing Tedopi, a neoepitope-based therapeutic cancer vaccine in non-small cell lung cancer and other solid tumors. It is a direct emerging competitor in the off-the-shelf therapeutic cancer vaccine category where NEUVOGEN's NGEN-143 operates.
- Nykode Therapeutics (formerly Vaccibody): Nykode Therapeutics develops DNA-based vaccines using its modular Vaccibody technology, including therapeutic cancer vaccine programs partnered with Regeneron and others. It is an emerging player in the off-the-shelf therapeutic vaccine space targeting solid tumors.
Broad incumbents
- Merck & Co. Merck is the leader in immuno-oncology with Keytruda (pembrolizumab), which is the most likely combination backbone for any therapeutic cancer vaccine including NEUVOGEN's NGEN-143. Merck's partnership with Moderna for mRNA-4157 sets a template for how it could engage with NEUVOGEN through licensing or co-development.
- Bristol Myers Squibb: BMS markets Opdivo (nivolumab) and Yervoy (ipilimumab) and acquired Juno Therapeutics, giving it leadership in both checkpoint inhibitors and cellular immunotherapies. As a checkpoint inhibitor leader and acquirer of cell therapy companies, BMS is a logical large-pharma counterpart or acquirer for NEUVOGEN.
- Dendreon (Sanpower Group): Dendreon developed and commercialized Provenge (sipuleucel-T), the first FDA-approved cellular immunotherapy for cancer (prostate cancer). Mark Frohlich, NEUVOGEN board member, was formerly CMO of Dendreon. Dendreon provides commercial precedent and reference points for the whole-cell cancer vaccine category NEUVOGEN operates in.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks5 records
Key highlights7 records
Customer concentration
NEUVOGEN social profiles
Digital presenceNEUVOGEN financial estimates
Financial estimateRevenue estimate
Valuation estimate
NEUVOGEN leadership team
Management profileNumber of profiles
Profiles20 records
NEUVOGEN funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
NEUVOGEN M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about NEUVOGEN
What does NEUVOGEN do?
NEUVOGEN develops therapeutic whole cell cancer vaccines for solid tumor indications using a proprietary platform that combines six genetically modified allogeneic tumor cell lines per vaccine product. Each cell line is enhanced with proprietary activation technology to broaden tumor antigen presentation and drive broad T cell responses. Vaccines are manufactured as off-the-shelf, intradermally administered products, with the lead candidate NGEN-143 targeting non-small cell lung cancer and nine additional candidates covering prostate, colorectal, breast, head and neck, glioblastoma, bladder, gastric, ovarian, and pancreatic cancers.
Is NEUVOGEN a public or private company?
NEUVOGEN is a private company. It is classified as venture growth investor backed and is currently operating.
When was NEUVOGEN founded?
NEUVOGEN was founded in -1. It employs 101 to 250 people.
Where is NEUVOGEN based?
NEUVOGEN is headquartered in San Diego, United States, in the North America region.
How does NEUVOGEN make money?
One revenue line is on record: therapeutic Cancer Vaccines.
Who are NEUVOGEN's main competitors?
Direct peers on record are Moderna, BioNTech, Gritstone bio and CureVac. Emerging players are Nouscom, OSE Immunotherapeutics and Nykode Therapeutics (formerly Vaccibody). Broad incumbents are Merck & Co., Bristol Myers Squibb and Dendreon (Sanpower Group).
Does NEUVOGEN have an API?
No public API is recorded for NEUVOGEN.
What industry is NEUVOGEN in?
NEUVOGEN's product category is Therapeutic Cancer Vaccines. Its primary akta.pro industry code is HLAIAEAG, Therapeutic Vaccines (e.g., Cancer/Chronic Infection), with a secondary code of HLAAAEAB, Therapeutic Vaccines (cancer, chronic infection immunotherapy). Its NAICS code is 325414 and its SIC code is 2836.